Rna Diagnostics is a specialized cancer diagnostics company focused on improving the management of cancer treatments through its innovative platform of predictive biomarkers. Founded in 2010, the company has developed the RNA Disruption Assay (RDA), a patented technology that provides real-time evaluations of how patients are responding to cancer therapies. This allows physicians to make informed decisions about continuing or altering treatment plans, thereby optimizing patient outcomes.

Operating primarily in the oncology diagnostics market, Rna Diagnostics serves healthcare providers, including hospitals and cancer treatment centers, across North America and Europe. The company generates revenue through the sale of its diagnostic tests and related services, which are utilized in clinical settings to guide cancer therapy decisions.

Rna Diagnostics recently completed phase 1 of the BREVITY trial, a large-scale international study aimed at validating the effectiveness of the RNA Disruption Assay in breast cancer treatment. The company has also secured a $5 million Series A financing round led by iGAN Partners to further its research and development efforts.

Keywords: cancer diagnostics, predictive biomarkers, RNA Disruption Assay, oncology, treatment management, real-time therapy guidance, clinical trials, breast cancer, healthcare providers, North America, Europe.